Baker Bros. Advisors LP bought $24.3M of KOD stock
By AlphaYouPublished Form 4
BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN
Reporting filer
Baker Bros. Advisors LP reported buying 247,090 shares of Kodiak Sciences Inc. for about $24.3M ($98.51 a share on average). Form 4 filed Nov 6, 2026 lists 4 entries.
See the price move since this trade →
- Disclosed
- Nov 6, 2026
Reported details
4 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | 2026-11-04 | P | Purchase | 8742 | 98.51 | 1,678,469 | 2 days | Filed terms
|
| Common Stock | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | 2026-11-04 | P | Purchase | 151916 | 98.51 | 20,343,130 | 2 days | Filed terms
|
| Common Stock | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | 2026-11-05 | P | Purchase | 4703 | 98.51 | 1,683,172 | 1 day | Filed terms
|
| Common Stock | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | 2026-11-05 | P | Purchase | 81729 | 98.51 | 20,424,859 | 1 day | Filed terms
|
Common Stock
- Owner
- BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN
- Date
- 2026-11-04
- Code
- P
- Action
- Purchase
- Quantity
- 8742
- Price
- 98.51
- Following holdings
- 1,678,469
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-11-04
- transaction Form Type: 4
- transaction Code: P
- equity Swap Involved: false
- transaction Shares: 8742
- transaction Price Per Share: 98.51
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 1678469
- direct Or Indirect Ownership: I
- nature Of Ownership: See Footnotes
- id: F1
- id: F2
- id: F3
Common Stock
- Owner
- BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN
- Date
- 2026-11-04
- Code
- P
- Action
- Purchase
- Quantity
- 151916
- Price
- 98.51
- Following holdings
- 20,343,130
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-11-04
- transaction Form Type: 4
- transaction Code: P
- equity Swap Involved: false
- transaction Shares: 151916
- transaction Price Per Share: 98.51
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 20343130
- direct Or Indirect Ownership: I
- nature Of Ownership: See Footnotes
- id: F2
- id: F3
- id: F4
Common Stock
- Owner
- BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN
- Date
- 2026-11-05
- Code
- P
- Action
- Purchase
- Quantity
- 4703
- Price
- 98.51
- Following holdings
- 1,683,172
- Reporting delay
- 1 day
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-11-05
- transaction Form Type: 4
- transaction Code: P
- equity Swap Involved: false
- transaction Shares: 4703
- transaction Price Per Share: 98.51
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 1683172
- direct Or Indirect Ownership: I
- nature Of Ownership: See Footnotes
- id: F1
- id: F2
- id: F3
Common Stock
- Owner
- BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN
- Date
- 2026-11-05
- Code
- P
- Action
- Purchase
- Quantity
- 81729
- Price
- 98.51
- Following holdings
- 20,424,859
- Reporting delay
- 1 day
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-11-05
- transaction Form Type: 4
- transaction Code: P
- equity Swap Involved: false
- transaction Shares: 81729
- transaction Price Per Share: 98.51
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 20424859
- direct Or Indirect Ownership: I
- nature Of Ownership: See Footnotes
- id: F2
- id: F3
- id: F4
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- BAKER BROS. ADVISORS LP: Director, 10% owner.
- 667, L.P.: Director, 10% owner.
- Baker Bros. Advisors (GP) LLC: Director, 10% owner.
- Baker Brothers Life Sciences LP: Director, 10% owner.
- BAKER FELIX: Director, 10% owner.
- BAKER JULIAN: Director, 10% owner.
- F1: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
- F2: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
- F3: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
- F4: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Original sources
Prepared automatically from public filing data. Report a correction.